medigraphic.com
ISSN 2448-8909 (Impreso)

2020, Número 1

<< Anterior Siguiente >>

Med Crit 2020; 34 (1)


SARS-CoV-2 y COVID-19. Una revisión de la pandemia

Elizalde GJJ

Idioma: Ingles.
Referencias bibliográficas: 84
Paginas: 53-67
Archivo PDF: 2002.57 Kb.


RESUMEN

Un nuevo peligro pone en alerta a toda la humanidad, retando a lo mejor de la misma para dar la batalla; se trata de la mutación de un nuevo virus el SARS-CoV-2, el tercero que cruza barreras en menos de dos décadas para infectar al ser humano. Iniciado a finales del año 2019 aparentemente en el mercado mayorista de mariscos y pescados de Wuhan en China, se ha extendido por todo el globo afectando seriamente a Europa y actualmente al continente americano y poniendo en jaque a los sistemas de salud de todas las naciones con un crecimiento exponencial de casos que pronto sumarán mundialmente más de un millón y medio en un corto periodo, la mayor parte de ellos con infección activa, un índice de letalidad cambiante, muchas preguntas clave sin contestar, un riesgo sustancial de transmisión nosocomial, un numero reproductivo básico (R0) mayor de 1 y sin un tratamiento específico que ofrecer. Las unidades de terapia intensiva, se espera puedan recibir cantidades crecientes de pacientes graves nunca antes vistas en la historia moderna de la medicina, poniendo a prueba su fuerza, organización y capacidad resolutiva, con imaginación, talento, trabajo, entrega y pasión. Se intenta hacer una revisión global del tema para centrar de mejor manera el problema que enfrentamos actualmente en todo el mundo y esperanzadamente permita plantear preguntas de investigación que sea factible contestar en un periodo más o menos breve a través de buenos protocolos de investigación, randomizados y controlados. Sólo con trabajo colaborativo y aplicando el método científico de manera sagaz e inteligente, podremos salir avantes de esta terrible amenaza que nos vuelve a mostrar lo frágil de nuestra naturaleza humana y la importancia de mantenernos dentro de rangos fisiológicos a lo largo de la vida.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. The 2019-nCoV Outbreak Joint Field Epidemiology Investigation Team, Li Q. Notes from the field: an outbreak of NCIP (2019-nCoV) infection in China-Wuhan, Hubei Province, 2019-2020. China CDC Weekly. 2020;2:79-80.

  2. Tan WJ, Zhao X, Ma XJ, et al. A novel coronavirus genome identified in a cluster of pneumonia cases. Wuhan, China 2019-2020. China CDC Weekly. 2020;2:61-62.

  3. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. Severe acute respiratory syndrome-related coronavirus: the species and its viruses. A statement of the Coronavirus Study Group. bioRxiv. 2020 Feb 11. doi: 10.1101/2020.02.07.937862.

  4. Shi ZL, Guo D, Rottier PJ. Coronavirus: epidemiology, genome replication and the interactions with their hosts. Virol Sin. 2016;31(1):1-2. doi: https://doi.org/10.1007/s12250- 016-3746-0.

  5. Perlman S. Another decade, another coronavirus. N Eng J Med. 2020;382(8):760-762. doi: 10.1056/NEJMe2001126.

  6. Andino R, Domingo E. Viral quasispecies. Virology. 2015;479-480:46-51.

  7. Domingo E, Sheldon J, Perales C. Viral quasispecies evolution. Microbiol Mol Biol Rev. 2012;76(2):159-216.

  8. Lauring AS, Andino R. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog. 2010;6(7):e1001005.

  9. Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24:490-502.

  10. Hui DS, Azhar EI, Kim YJ, Memish ZA, Oh MD, Zumla A. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis. 2018;18:e217-e227.

  11. Cheng PK, Wong DA, Tong LK, et al. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. Lancet. 2004;363:1699-700.

  12. Yan R, Zhang Y, Li Y, Xia L. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444-1488. doi: 10.1126/science.abb2762.

  13. Zhou P, Yang XL, Wang XG, Hu B, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv. 2020 January 23. doi.org/10.1101/2020.01.22.914952.

  14. Giebisch G, Windhager EE, Aronson PS. Integración del balance de las sales y el agua. En: Boron WF, Boulpaep EL (eds.). Fisiología médica. 3a edición. España: Elsevier; 2017. Capítulo 40: pp. 836-849.

  15. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020 Feb 21. doi: 10.1001/jama.2020.2565.

  16. Bavishi C, Maddox TM, Messerli FH. Coronavirus Disease 2019 (COVID-19) infection and renin angiotensin system blockers. JAMA Cardiol. 2020 Apr 3. doi: 10.1001/jamacardio.2020.1282.

  17. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, et al. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Eng J Med. 2020 March 30. doi: 10.1056/NEJMsr2005760.

  18. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63(3):364-374. doi: 10.1007/s11427-020-1643-8.

  19. Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005;202:415-24.

  20. Perlman S. Another decade, another coronavirus. N Engl J Med. 2020;382(8):760-762. doi: 10.1056/NEJMe2001126.

  21. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8.

  22. Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A novel coronavirus emerging in China - key questions for impact assessment. N Engl J Med. 2020;382(8):692-694. doi: 10.1056/NEJMp2000929.

  23. The 2019-nCoV Outbreak Joint Field Epidemiology Investigation Team, Li Q. Notes from the field: an outbreak of NCIP (2019-nCoV) infection in China. Wuhan, Hubei Province, 2019–2020. China CDC Weekly. 2020;2:79-80.

  24. Tan WJ, Zhao X, Ma XJ, et al. A novel coronavirus genome identified in a cluster of pneumonia cases. Wuhan, China 2019-2020. China CDC Weekly. 2020;2:61-62.

  25. Li X, Zai J, Wang X, Li Y. Potential of large “first generation” human-to-human transmission of 2019-nCoV. J Med Virol. 2020;92(4):448-454. doi: 10.1002/jmv.25693.

  26. Xiang N, Havers F, Chen T, Song Y, Tu W, Li L, et al. Use of national pneumonia surveillance to describe influenza A(H7N9) virus epidemiology, China, 2004-2013. Emerg Infect Dis. 2013;19(11):1784-1790. doi: 10.3201/eid1911.130865.

  27. The 2019-nCoV Outbreak Joint Field Epidemiology Investigation Team, Li Q. Notes from the field: an outbreak of NCIP (2019-nCoV) infection in China. Wuhan, Hubei Province, 2019-2020. China CDC Weekly. 2020;2:79-80.

  28. Xiang N, Havers F, Chen T, et al. Use of national pneumonia surveillance to describe influenza A(H7N9) virus epidemiology, China, 2004-2013. Emerg Infect Dis. 2013;19:1784-1790.

  29. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). Science. 2020 Mar 16. pii: eabb3221. doi: 10.1126/science.abb3221. [Epub ahead of print]

  30. Perlman S, McCray PB. Person-to-person spread of the MERS coronavirus. An evolving picture. N Engl J Med. 2013;369(5):466-467.

  31. Zhu N, Zhang D, Wang W, Li X, et al. A Novel coronavirus from patients with pneumonia in China, 2019. N Eng J Med. 2020 January 24. doi: 10.1056/NEJMoa2001017.

  32. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 January 24. doi: 10.1016/S0140-6736(20)30154-9.

  33. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181-192.

  34. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199-1207. doi: 10.1056/NEJMoa2001316.

  35. Bauch CT, Lloyd-Smith JO, Coffee MP, Galvani AP. Dynamically modeling SARS and other newly emerging respiratory illnesses: past, present, and future. Epidemiology. 2005;16:791-801.

  36. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14:523-534.

  37. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970-971. doi: 10.1056/NEJMc2001468.

  38. Zhou F, Yu T, Du R, Fan G, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-1062.

  39. Guan W, Ni Z, Hu Y, Liang W, et al. Clinical characteristics of coronavirus disease 2019 in China. N Eng J Med. 2020. doi: 10.1056/NEJMoa2002032.

  40. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970-971. doi: 10.1056/NEJMc2001468.

  41. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970-971. doi: 10.1056/NEJMc2001468.

  42. Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA. 2020 Mar 13. doi: 10.1001/jama.2020.4031.

  43. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, et al. Covid-19 in critically ill patients in the seattle region-case series. N Eng J Med. 2020 March 30. doi: 10.1056/NEJMoa2004500.

  44. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.

  45. Zhou F, Wang Y, Liu Y, Liu X, et al. Disease severity and clinical outcomes of community acquired pneumonia caused by non-influenza respiratory virus: a multicenter prospective registry study from CAP-China network. Eur Respir J. 2019;54(2). pii: 1802406. doi: 10.1183/13993003.02406-2018.

  46. Chang D, Gouxin M, Yuan X, Tao Y, et al. Time kinetics of viral clearance and resolution of symptoms in novel coronavirus infection. Am J Respir Crit Care Med. 2020 March 23. doi: 10.1164/rccm.202003-0524LE.

  47. Smits SL, de Lang A, van den Brand JMA, et al. Exacerbated innate host response to SARS-CoV in aged non-human primates. PLoS Pathog. 2010;6 e1000756-e.

  48. Opal SM, Girard TD, Ely EW. The immunopathogenesis of sepsis in elderly patients. Clin Infect Dis. 2005;41(suppl 7):S504-S512.

  49. General Office of National Health Committee. Office of State Administration of Traditional Chinese Medicine. Notice on the issuance of a programmed for the diagnosis and treatment of novel coronavirus (2019-nCoV) infected pneumonia (Trial Version 4). 2020. Available in: http://bgs.satcm.gov.cn/ zhengcewenjian/2020-01-28/12576.html. Accessed 9 Feb 2020.

  50. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUS of the Lombardy region, Italy. JAMA. 2020 April 6. doi: 10.1001/jama.2020.5394.

  51. Whitley R. The new age of molecular diagnostic for microbial agents. N Eng J Med. 2018;358:988-989. doi: 10.1056/NEJMp0708085.

  52. Omer SB, Malani P, del Rio C. The COVID-19 pandemic in the US. A clinical update. JAMA. 2020 April 6. doi: 10.1001/jama.2020.5788.

  53. Wang W, Xu Y, Gao R, Lu R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020 March 11. doi: 10.1001/jama.2020.3786.

  54. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.

  55. The ARDS Definition Task Force. Acute respiratory distress syndrome. The Berlin definition. JAMA. 2012;307(23):2526-2533. doi: 10.1001/jama.2012.5669.

  56. Thompson BT, Chambers RC, Liu KD. Acute respiratory distress syndrome. N Engl J Med. 2017;377(6):562-572. doi: 10.1056/NEJMra1608077.

  57. Highfield J. Advice for sustaining staff wellbeing in critical care during and beyond COVID-19. Intensive Care Society. www.ics.ac.uk

  58. Xu Z, Shi L, Wang Y, Zhang J, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X.

  59. Jones R, Reid LM, Zapol WM, et al. Pulmonary vascular pathology, human and experimental studies. In: Zapol WM, Falke KJ (eds.). Acute respiratory failure. New York: Marcel Dekker, INC.; 1985. pp. 23-160.

  60. Zapol WM, Snider MT. Pulmonary hypertension in severe acute respiratory failure. N Eng J Med. 1977;296:476-480.

  61. Tomashefski JF, Davies P, Boggis L, et al. The pulmonary vascular lesions of the adult respiratory distress syndrome. Am J Pathol. 1983;112:112-126.

  62. Greene R, Zapol WM, Snider MT, et al. Early bedside detection of pulmonary vascular occlusion during acute respiratory failure. Am Rev Respir Dis. 1981;124:593-601.

  63. Liao X, Wang B, Kang Y. Novel coronavirus infection during the 2019-2020 epidemic: preparing intensive care units-the experience in Sichuan Province, China. Intensive Care Med. 2020;46(2):357-360. doi: 10.1007/s00134-020-05954-2.

  64. Murthy S, Gomersall CD, Fowler RA. Care for critically ill patients with COVID-19. JAMA. 2020 Mar 11. doi: 10.1001/jama.2020.3633.

  65. Elizalde GJJ. Complicaciones extrapulmonares en neumonía por influenza AH1N1. In: Pérez PJR (ed.). Influenza por el nuevo virus AH1N1. Un panorama integral. México City: Graphimedic; 2010. Chapter 21: pp. 268-282. (Spanish)

  66. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020 Mar 28. doi: 10.1007/s00134-020-06022-5.

  67. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020 Mar 19. doi: 10.1001/jama.2020.4326.

  68. Johns Hopkins University Center for Systems Science and Engineering. Coronavirus COVID-19 Global Cases by Johns Hopkins CSSE. Available at: https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6. Accessed March 21, 2020. (Johns Hopkins epidemiologic tracking website)

  69. World Health Organization. First data on stability and resistance of SARS coronavirus compiled by members of WHO laboratory network. Geneva, Switzerland: World Health Organization; 2003. Available in: http://www.who.int/csr/sars/survival_2003_05_04/en/index.html.

  70. Casanova LM, Jeon S, Rutala WA, Weber DJ, Sobsey MD. Effects of air temperature and relative humidity on coronavirus survival on surfaces. App Envirom Microbiol. 2010;76(9):2712-2717.

  71. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924.

  72. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69-71.

  73. Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. 2020 Mar 20. pii: eabb3405. doi: 10.1126/science.abb3405.

  74. Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J. 2010;36:646-54. doi: 10.1183/09031936.00095809.

  75. Min JY, Jang YJ. Macrolide therapy in respiratory viral infections. Mediators Inflamm. 2012;2012:649570. doi: 10.1155/2012/649570.

  76. Menzel M, Akbarshahi H, Bjermer L, Uller L. Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients. Sci Rep. 2016;6:28698. doi: 10.1038/srep28698.

  77. Savarino A, Boelaert JR, Cassone A, Majori G, et al. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003;3(11):722-727.

  78. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7(1):11. doi: 10.1186/s40779-020-00240-0.

  79. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA. Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest. 1987;92(6):1032-1036.

  80. Zhao ZW, Zhang FC, Xu M, Huang K, Zhong WN, Cai WP, et al. Clinical analysis of 190 cases of outbreak with atypical pneumonia in Guangzhou in spring, 2003. Zhonghua Yixue Zazhi. 2003;83(9):713-718.

  81. Meng QH, Dong PL, Guo YB, Zhang K, Liang LC, Hou W, et al. Use of glucocorticoid in treatment of severe acute respiratory syndrome cases. Zhonghua Yufang Yixue Zazhi. 2003;37(4):233-235.

  82. Wu C, Chen X, Cai Y, Xia J, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020 Mar 13. doi: 10.1001/jamainternmed.2020.0994.

  83. Jin YH, Cai L, Cheng ZS, Cheng H, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7(1):4. doi: 10.1186/s40779-020-0233-6.

  84. National Health Commission (NHC) of the People’s Republic of China. National Administration of Traditional Chinese Medicine of the PRC. Guidance for Corona Virus Disease 2019. Prevention, Control, Diagnosis and Management. ISBN 978-7-117-29817-9. Available in: http://www.pmph.com/




2020     |     www.medigraphic.com